Press releases
- Henlius Trastuzumab Receives FDA Approval in the United States
- Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
- Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
- Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
Key statistics
On Wednesday, Shanghai Henlius Biotech Inc (2696:HKG.HZ) closed at 18.84, -0.53% below its 52-week high of 18.94, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.84 |
---|---|
High | 18.84 |
Low | 18.84 |
Bid | -- |
Offer | -- |
Previous close | 18.84 |
Average volume | 466.63k |
---|---|
Shares outstanding | 543.49m |
Free float | 81.69m |
P/E (TTM) | 17.45 |
Market cap | 10.24bn HKD |
EPS (TTM) | 1.08 HKD |
Data delayed at least 15 minutes, as of May 29 2024.
More ▼